Lonza acquires the bioproducts manufacturing division of UCB

By Lisa Kerner

Erie, Pa., Jan. 17 - Lonza and UCB jointly announced that Lonza has acquired the bioproducts manufacturing division of UCB for €120 million. Other terms of the acquisition were not released.

"We are quite excited to welcome the fully dedicated, highly qualified and entrepreneurial UCB colleagues to join our global business," Stefan Borgas, Lonza chief executive officer said in a company release. "With this acquisition Lonza further strengthens its position as a worldwide leader in custom peptide manufacturing by continuing to develop the Braine l'Alleud site as a global centre of excellence for the development and manufacture of peptides."

"This transaction is another strategic move towards UCB's quest of becoming a global biopharmaceutical leader focusing on research, development, and commercialization of therapeutic solutions for severe diseases," Roch Doliveux, UCB chief executive officer, added in the release.

The expertise in liquid phase technology developed by UCB bioproducts division complements Lonza's existing peptide production, with a focus on large-scale solid phase peptide synthesis, and recombinant fermentation production, said officials.

Lonza is a chemical and biotechnology company with headquarters located in Basel, Switzerland.

UCB is a biopharmaceutical company specializing in products for the central nervous system disorders, inflammatory diseases, and oncology. The company is based in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.